TM4-B Activators
TM4-B employ a variety of mechanisms to elevate intracellular cAMP levels, leading to activation of protein kinase A (PKA), which can then target TM4-B for phosphorylation. Forskolin is directly involved in this process; it activates adenylate cyclase, which catalyzes the conversion of ATP to cAMP. This increase in cAMP levels activates PKA, which can phosphorylate and thus activate TM4-B. Similarly, isoproterenol, a beta-adrenergic agonist, binds to beta receptors, leading to G protein activation, which then stimulates adenylate cyclase, resulting in elevated cAMP levels and subsequent PKA-mediated phosphorylation of TM4-B. Another agent, PGE2, functions through its interaction with G protein-coupled receptors to increase cAMP and activate PKA, potentially leading to TM4-B activation. Histamine operates through H2 receptors to produce the same outcome, as does dopamine through D1-like receptors and adenosine through A2A or A2B receptors, all culminating in PKA activation and potential TM4-B phosphorylation.
Glucagon and epinephrine engage with their respective GPCRs to stimulate adenylate cyclase, thereby increasing cAMP and activating PKA, which can then act on TM4-B. Cholera toxin exacerbates this pathway by catalyzing the ADP-ribosylation of the Gs alpha subunit, resulting in prolonged adenylate cyclase activation, increased cAMP levels, and sustained PKA activity, which may lead to TM4-B activation via phosphorylation. Anagrelide and rolipram, by inhibiting phosphodiesterase III and IV, respectively, prevent the breakdown of cAMP, further enhancing PKA activity and the potential for TM4-B phosphorylation. IBMX, as a non-selective inhibitor of phosphodiesterases, similarly increases cAMP levels and activates PKA, offering another route to TM4-B activation. Each of these chemicals, through their distinct interactions with cellular signaling pathways, contributes to the regulation of TM4-B activity by modulating the cAMP-PKA signaling axis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, binds to beta receptors, leading to G protein activation, which in turn activates adenylate cyclase, increasing cAMP levels. The increase in cAMP activates PKA, potentially leading to the activation of TM4-B through phosphorylation if TM4-B is part of the cAMP/PKA signaling pathway. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) interacts with its G protein-coupled receptors (GPCRs), leading to an increase in intracellular cAMP levels, which activate PKA. PKA can then activate TM4-B through phosphorylation if TM4-B is a substrate or associated with the PKA signaling cascade. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine can bind to H2 receptors, which are GPCRs that activate adenylate cyclase, leading to an increase in cAMP and subsequent activation of PKA. PKA may then activate TM4-B by phosphorylation if TM4-B is functionally connected to the PKA signaling axis. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine interacting with D1-like receptors can increase cAMP levels by activating adenylate cyclase via Gs proteins, leading to activation of PKA. PKA may then phosphorylate and activate TM4-B if TM4-B is aligned with the dopamine D1-like receptor signaling pathway. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine binds to A2A or A2B receptors, which are GPCRs that activate adenylate cyclase, increasing cAMP levels and activating PKA. PKA may phosphorylate and activate TM4-B if TM4-B is part of the adenosine receptor signaling pathway. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to beta-adrenergic receptors, activating G proteins that stimulate adenylate cyclase, increasing cAMP, and activating PKA. PKA can then activate TM4-B by phosphorylation if TM4-B is involved in beta-adrenergic signaling. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits phosphodiesterase III (PDE3), leading to an accumulation of cAMP within the cell. This accumulation activates PKA, which may activate TM4-B through phosphorylation if TM4-B is within the PDE3 signaling axis. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram selectively inhibits PDE4, preventing cAMP breakdown, which results in PKA activation. PKA can then phosphorylate and activate TM4-B if TM4-B is a target of PKA within the PDE4 signaling pathway. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP levels and PKA activation. PKA can then activate TM4-B through phosphorylation if TM4-B is a part of pathways regulated by cAMP levels. | ||||||